Reaction
Skin Neoplasm Excision reporting signals
As of the last recalculation, Skin Neoplasm Excision appears in 771 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is BENDAMUSTINE HYDROCHLORIDE (PRR 36.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Bendamustine Hydrochloride | 16 | 36.8 | 36.9 |
| Doxyclycline Hyclate | 22 | 35.9 | 35.9 |
| Bendamustine Hcl | 20 | 35.7 | 35.8 |
| Pramipexole | 15 | 26.9 | 27.0 |
| Cyanocobalamin | 31 | 26.4 | 26.5 |
| Tofacitinib Citrate | 11 | 23.0 | 23.0 |
| Abatacept | 89 | 19.5 | 19.5 |
| Certolizumab Pegol | 62 | 15.4 | 15.5 |
| Relugolix | 12 | 13.9 | 13.9 |
| Golimumab | 40 | 13.2 | 13.2 |
| Bimekizumab | 10 | 12.8 | 12.8 |
| Bortezomib | 34 | 10.7 | 10.7 |
| Vibegron | 3 | 10.1 | 10.1 |
| Ixekizumab | 12 | 8.9 | 8.9 |
| Encorafenib | 3 | 8.2 | 8.2 |
| Patiromer | 3 | 5.9 | 5.9 |